IP Library Patent Application 12345385
Patent Application
App. No. 12/345,385

MATERIALS FROM BONE MARROW STROMAL CELLS FOR USE IN FORMING BLOOD VESSELS AND PRODUCING ANGIOGENIC AND TROPHIC FACTORS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/345,385
Abstract

A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the stem cells with a compound for increasing the production of angiogenesis and vasculogenesis inducing factors. Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use in a therapy. A process for obtaining the angiogenesis and vasculogenesis inducing factors as set forth above, the process including the steps of isolating and purifying human mesenchymal stem cells from tissue prior to differentiation and then culture expanding the mesenchymal stem cells to produce a tool for neurological and musculoskeletal therapy. Isolated and culture expanded mesenchymal stem cells under the influence of a requisite compound, that are capable of differentiating and producing a desired cell phenotype needed for tissue repair.

Claims (11)

1 . A therapeutic for use in inducing angiogenesis and vasculogenesis, said therapeutic comprising angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharamaceutically acceptable cell therapeutic, said therapeutic for inducing angiogenesis and vasculogenesis.

2 . The therapeutic according to claim 1 , wherein said angiogenesis and vasculogenesis inducing factors are selected from the group consisting essentially of angiogenic, trophic, and growth factors.

3 . The therapeutic according to claim 1 , wherein said cell therapeutic is a stem cell that is selected from the group consisting essentially of mesenchymal stem cells, stromal cells and precursors thereof, fibroblasts, reticulocytes, adipocytes, and endothelial cells.

4 . A method of amplifying production of angiogenesis and vasculogenesis inducing factors secreted from stromal cells by exposing to and co-culturing stromal cells with a differentiation-inducing compound for increasing the production of the angiogenesis and vasculogenesis inducing factors.

5 . The method according to claim 4 , wherein said method includes exposing to and co-culturing stromal cells with a differentiation-inducing compound for increasing the production of the angiogenesis and vasculogenesis inducing factors, said differentiation-inducing compound being selected from the group consisting essentially of brain extract and calcium.

6 . Angiogenesis and vasculogenesis inducing factors isolated and purified from stem cells for use as a therapy.

7 . The angiogenesis and vasculogenesis inducing factors according to claim 6 , wherein the angiogenesis and vasculogenesis inducing factors induce angiogenesis and vasculogenesis upon administration to a patient in need of such treatment.

8 . The angiogenesis and vasculogenesis inducing factors according to claim 6 , wherein said angiogenesis and vasculogenesis inducing factors are factors secreted by stem cells when exposed to and co-cultured with a differentiation-inducing compound for increasing the production of desired factors.

9 . The angiogenesis and vasculogenesis inducing factors according to claim 8 , said differentiation-inducing compound being selected from the group consisting essentially of brain extract and calcium.

10 . The angiogenesis and vasculogenesis inducing factors according to claim 9 , wherein said brain extract is selected from the group consisting essentially of brain cells, cells obtained from the brain, and supernatant from stromal cells cultured with a medium.

11 .- 20 . (canceled)

Assignments (1)
LIEN Recorded Apr 30, 2009
From: ARTECEL, INC.; COGNATE BIOSERVICES, INC.; THERADIGM, INC.
To: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC
Reel/Frame 022619/0065 →